

Johnson & Johnson

Sirturo[®] – the South African Story

Abeda Williams

Senior Director: J&J Global Public Health

Johnson & Johnson

© Janssen Pharmaceutica Pty Ltd 2023 Not for further reproduction or distribution without consent.

GLOBAL PUBLIC HEALTH

The beginning of a partnership with government

1

Early Access Programme

- J&J donated 200 units for pre-XDR and XDR patients at 12 designated sites

2

Funding

- Training HCP's
- Donation of ECG and portable audiometers to monitor for safety signal

3

Lesson Learnt



4

Outcomes

- >75% Treatment success
- 12% Mortality

South Africa Impact:

Platform to expand Sirturo[®] access to all pre-XDR and XDR patients, effecting changes in guideline(s) (injection free regimen)

Global Impact:

WHO guidelines changed based on RWE generated in South Africa

Reflections on change in South Africa

BHEKISISA
CENTRE FOR HEALTH JOURNALISM

HOME ABOUT US ▾ OPINION NEWS & ANALYSIS

RESOURCES ▾

But new drugs that are being piloted in South Africa could change this.



Get involved Work with us About us Articles & publications

STAFF & PATIENT STORY

Tuberculosis: A choice beyond deafness and death



News

Africa | Asia-Pacific | Europe | Latin America & the Car

Home Development & Aid Economy & Trade Environment Human Rights Global Governance

Featured, Global, Headlines, Health, Population, Poverty & SDGs, TerraViva United Nations

OPINION

Deaf or Dead? The Unbearable Choice for some TB Patients

By Phumeza Tisile

Reprint | [f](#) [t](#) [in](#) [v](#) | [Print](#) | [Send by email](#)

Phumeza Tisile is a student at the University of Cape Town and an advocate working to help eradicate TB

CAPE TOWN, Oct 3 2018 (IPS) - Like death, hearing loss is irreversible. I never imagined that I would have to choose between the two until seven years ago when I became infected with tuberculosis (TB), a contagious disease caused by an airborne bacterium.

Patient Feedback

“I am a grade 12 learner diagnosed with full-blown XDR TB on 25th February 2014. All thanks to everyone who made it possible for me to be a trial runner for Bedaquiline. I am healthy, I feel healthy and much better, and my sputum has converted and stayed negative since April 2014. Drawing towards the end of this month I will be finishing up my 24 weeks in patient treatment. Thank God and all doctors, other health professionals as well as professors who made this possible.”

Reflections on change in South Africa

“Experiences like these make me feel grateful that I treat TB in South Africa, a country that publicly declared in June 2018 that bedaquiline would be offered to drug-resistant TB patients in place of the toxic antibiotic that can cause deafness. This bold announcement followed the publication of some data by South Africa’s Department of Health, demonstrating that people who had received bedaquiline were four times less likely to die from drug-resistant TB.”

-Dr Anja Reuter, 27 November 2018

<http://www.tbonline.info/posts/2018/11/27/old-tb-treatments-result-deafness-and-death/>

Private sector engagement

Finding the missing cases in the private sector

Partnership with Aquity, US Embassy and *National TB program* convened a meeting with private sector stakeholders to seek commitment:

- **TB in the workplace:** education and screening within the workspace and associated community.
- **Innovation in TB:** private sector to share contributions towards innovations in communication, transport/deliver, reporting and monitoring and use of information technology for improved TB management.
- **Mass screening campaigns:** Community screening to identify missing TB cases



Communication social mobilisation strategy – How will I know?



Sirturo®: an example of private public partners which improved patient outcomes

South Africa take-aways

- Government commitment and political will for change.
- Collaboration with government where they need it the most.
- Focused primarily on public sector and then private sector engagement to ensure package of care is equitable.
- Working with credible implementing partners.
- Generating RWE to drive guideline change and implementation prior to WHO.
- Global implications: Doing locally, acting globally.

Global take-aways

- Disease concentrated in RLS with poor access to healthcare
- Key success factors
 1. WHO regulatory waiver to overcome registration challenge to accelerate access;
 2. Collaboration with all stakeholders to scale availability and access
 3. Catalytic partnerships to ignite stagnant innovation by capacity building success factors, patient support and education programs
- Other countries modelled programmed on South Africa approach (eg India, China, Indonesia)

623,331 doses shipped since first approval
159 countries have now accessed

Thank you.